BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over thirteen years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries.
With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets.
BioLargo Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page.
Please refer to the important disclosures below for additional details.
BioLargo Inc. (BLGO:OTCQX) says its BEST subsidiary is running two paid PFAS treatment pilots for industrial clients as companies like 3M agree to multibillion-dollar settlements over forever chemicals. Find out why one analyst likes the company's strategy of proving its technologies before partnering to bring them to market.
BioLargo Inc. (BLGO:OTCQX) launched barebird™, a consumer odor-elimination brand it owns, built on its CupriDyne technology and backed by the marketing teams behind Pooph. Find out why one analyst says BioLargo's "hub and spoke" business model spreads its risk.
BioLargo Inc. (BLGO:OTCQX) is organizing to run commercial trials for its water treatment solutions in northern Alberta and has helped form Tũ Nipi Water Solutions, an Indigenous-led venture backed by a conditional grant commitment from Emissions Reduction Alberta. Find out why one analyst likes how the company spreads its risk.
BioLargo subsidiary Clyra enters an exclusive reseller agreement with Spartan Medical for ViaCLYR wound care solution targeting U.S. government facilities and ECAT listing amid expanding wound care demand.
BioLargo Inc. (BLGO:OTCQX) is bringing its FDA-cleared ViaCLYR wound solution to U.S. government and VA-contracted healthcare facilities through a new deal with Spartan Medical.
BioLargo reports 26% revenue growth excluding exited line, 54% gross margins and subsidiary-led funding model across medical, water and energy businesses.
Cleantech innovator BioLargo Inc. (BLGO:OTCQX) files its financial results for the three and six months ended June 30. Find out how the company funded its five businesses while raising 86% of its capital without selling BioLargo stock.
BioLargo's AEC technology has treated over 2 million gallons of PFAS-contaminated water in New Jersey while meeting regulatory standards. Learn how the system reduces waste and costs compared with traditional methods.
BioLargo Inc. (BLGO:OTCQX) announces the processing of more than 2 million gallons of PFAS-contaminated water using its patented Aqueous Electrostatic Concentrator (AEC) technology. Find out why one technical analyst likes BLGO's business model.
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way.
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.
BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note
BioLargo Inc. (BLGO:OTCQX) says a subsidiary has secured a US$1.2 million contract to design of a pilot-scale facility to reuse legacy mine waste in the Western U.S. One expert says the company has multiple catalysts approaching.
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii.
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives.
BioLargo Inc. (BLGO:OTCQX) announces that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed in New Jersey. Find out why the company sees massive upside for its products.
BioLargo Inc. (BLGO:OTCQX) has announced the installation of its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system in New Jersey. Discover why the company anticipates significant potential for its products.
BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert notes the company is looking forward to its part in "what may be one of the largest infrastructure and technology investment cycles in history."
Dennis P. Calvert, President and CEO of BioLargo Inc. (BLGO:OTCQX), mentions that the company is eager to participate in "what may be one of the largest infrastructure and technology investment cycles in history."
BioLargo Inc. (BLGO:OTCQX) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) is prominently featured in Chemical Engineering magazine for its advancements in electrostatic PFAS treatment technology. Find out why one expert likes this stock long-term.
Chemical Engineering magazine features BioLargo Inc. (OTCQX:BLGO) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) for its advancements in electrostatic PFAS treatment technology. Read why one expert likes this stock long-term.
Clean technology innovation company BioLargo Inc. releases its financial and operational results for the three- and nine-month periods ending September 30. It also has announced an agreement to distribute its cutting-edge wound irrigation solution nationally.
BioLargo Inc. (BLGO:OTCQX) announces a significant upgrade to its patented Aqueous Electrostatic Concentrator (AEC) system, reducing energy consumption by over 90% in large-scale "forever chemical" treatment for drinking water.
Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization."
Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future.
Environmental and cleantech company BioLargo Inc. (BLGO:OTCQX) announces its financial results, including a huge increase in revenue in its engineering segment due to contracts to provide control compliance services.
BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report.
Clean technology company BioLargo Inc. (BLGO:OTCQX) president and chief executive office shares a mid-year update on the company's achievements so far this year, along with insights into its future prospects through a letter to shareholders.
BioLargo Inc. (BLGO:OTCQX) announced it has initiated "alpha testing" of a PFAS-detecting portable water test kit. Find out why one analyst says the stock is a Buy.
BioLargo Inc. (BLGO:OTCQX) announces that an independent evaluation has validated significant benefits of its Cellinity battery technology for use in grid-scale energy storage systems. Read why the report says the product is positioned as a "potential solution for critical gaps in grid-scale energy storage markets."
BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report.
Clean technology company BioLargo Inc. (BLGO:OTCQX) announced case study data on the cost savings of its Aqueous Electrostatic Concentrator (AEC) solution for removing "forever chemicals" from water. Read why one analyst says you shouldn't pass this stock by.
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story.
Clean technology company BioLargo Inc. (BLGO:OTCQX) will present data on its industry-leading PFAS capture and destruction solution at an industry conference this week. Read why one analyst says the technology has a "large and growing" pipeline of opportunities.
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces it had a "widely successful" and "transformative" 2024 and is looking forward to more revenue growth in 2025. Read why one expert thinks investors should be doubling down on the stock.
Clean technology company BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert has been appointed by the U.S. Secretary of Commerce to serve on an environmental technologies trade committee. One analyst says the company's growing reputation "should not be overlooked."
Clean technology company BioLargo Inc. (BLGO:OTCQX) says its 2024 revenues through September 30 were 80% greater than in the same period last year. One analyst believes the stock is "significantly undervalued."
BioLargo Inc. (BLGO:OTCQX) recently validated key performance metrics for its Cellinity battery technology, designed to address long-duration energy storage needs. See what these tests verify and why the CEO is very excited for the future of the company.
Clean technology company BioLargo Inc. (BLGO:OTCQX), which has developed technology to "forever chemicals" from water, will participate in a symposium on the contaminants in New York. One analyst says the company's growing validation in the field should "not be overlooked."
The company's Pooph line of pet odor eliminating products "continues to experience strong commercialization growth," noted an Oak Ridge Financial Research report.
Clean technology company BioLargo Inc. (BLGO:OTCQX) continues to see rising revenues with strong year-over-year and quarter-over-quarter growth. Find out why one analyst recommends investors look at the stock.
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces preliminary financial results for the second quarter ending June 30, 2024, including a 247% increase in revenue QoQ. One analyst says the stock is headed for an upleg.
So-called "forever chemicals" used by industry in water and food are becoming more ubiquitous worldwide, researchers said, even in lithium-ion batteries powering the energy transition. One company has solutions.
With Electric Vehicles (EVs) and a swarm of new products requiring more power, experts agree that a surge in demand is coming, and soon. Here are several companies that can get you exposure to this important and growing resource.
Research is showing that more of us and more parts of us are being exposed to so-called "forever chemicals." BioLargo Inc. (BLGO:OTCQB) said its technology removes 99% of them.
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic.
Clean technology company BioLargo Inc. (BLGO:OTCQB) announced it has manufactured its "liquid sodium" prototype battery cells that it says are long-lasting and safer than lithium-ion batteries. One technical analyst said the stock is a great spot to buy.
Clean tech company BioLargo Inc. (BLGO:OTCQB) announced its engineering subsidiary has been awarded a contract to provide air quality services at three New Mexico U.S. Air Force bases. The company is also seeing success with its pet odor control product and its solution to treat so-called "forever chemicals."
New research is revealing more bad news about just how far "forever chemical" pollution reaches in North America, pointing to an even bigger need for technology like BioLargo Inc.'s treatment systems for removing them.
BioLargo Inc. announced record quarterly revenues of US$4.76 million for the three months ending March 31, a 28% increase over the first quarter of 2023. Find out why one analyst sees a bull market coming for the company.
As the U.S. federal government continues to crackdown on so-called "forever chemicals," one company said its technology could help localities comply with the regulations. One technical analyst is predicting a breakout in the company's stock.
Utilities could use this technology, which reduces PFAS in water, to meet the new standards for public drinking water, noted an Oak Ridge Financial report.
BioLargo Inc. may be uniquely positioned to take advantage of new U.S. federal drinking water standards announced Wednesday meant to limit exposure to so-called "forever chemicals." Find out why one technical analyst says this stock is headed for a bull market.
The controversy over dangerous PFAS, also known as "forever chemicals," has hit two small farms in Texas. Find out why one analyst thinks a company with a solution is headed for a bull market as its stock rises.
Almost half of the nation's tap water is affected by so-called "forever chemicals." Find out if these dangerous substances have been found in waters near you.
By hiring the longest-serving CEO of the Metropolitan Water District of Southern California, BioLargo, Inc. has positioned itself as a leader of a nascent industry.
Clean tech company BioLargo Inc. is launching a new subsidiary to capitalize on its treatment technologies ridding water of so-called "forever chemicals." One analyst says the pipeline of potential projects is growing.
The potential stock-boosting events for this U.S. company include product launches, an inked partnership and revenue generation. Read more about them here.
You've been hearing plenty about the importance and scarcity of lithium for powering electric vehicles (EVs) in the battle to stop climate change. But another, humbler, element may also be on the table: Salt.
Technical Analyst Clive Maund takes a look at BioLargo Inc.'s 20-year, 19-month, and 6-month charts to explain why he believes a new bull market may be incubating for this clean tech company.
More than 200 million Americans could have harmful "forever chemicals" in their drinking water, and this clean tech company says 99% of them can be removed by its technology.
BioLargo Inc.'s hit pet odor control product Pooph is launching at more than 20,000 stores this year, a tenfold increase in its current retail store count. The company also announced a 127% increase in year-to-date revenues compared to the last period. Read to see the press release, and what catalysts Biolargo sees coming its way.
This clean tech company's approach to addressing everything from "forever chemicals" in the environment to stubborn pet odors is about to payoff, an analyst says.
BioLargo Inc.'s pet odor control product, Pooph, is "taking the market by storm." Find out how this company is a 'Strong Buy,' according to one analyst.
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news.
Shares of this green technology company have bottomed out, making it a good time to buy back any positions sold or add to existing ones, analyst Clive Maund says.
Chris Temple of The National Investor explains why he has issued a speculative buy recommendation for BioLargo, a small-cap company with a flagship product that removes certain contaminants from water.
In an article for Streetwise Reports, Penny Queen explains how environmental engineering company, BioLargo Inc., is on track to "make shareholders' portfolios better."
"BioLargo Inc. successfully installed its proprietary Aqueous Electrostatic Concentrator at a municipal water treatment plant in Lake Stockholm, N.J. . .the company's subsidiary Clyra Medical Technologies recently completed its first production run for nonsurgical wound irrigation solution ViaClyr."
Richard Ryan, Oak Ridge Financial
(11/19/25)
"BioLargo Inc. subsidiary Clyra Medical Technologies formalized a relationship with Advanced Solution LLC to distribute ViaCLYR, Clyra's innovative wound irrigation solution, in the U.S. . .[the] product is getting prepared to launch, which could occur by year-end, but more likely early 2026."
More Expert Comments
Richard Ryan, Oak Ridge Financial
(10/30/25)
"ViaCLYR, an advanced wound irrigation and antimicrobial solution of BioLargo Inc. subsidiary, Clyra Technologies, remains on schedule for commercial launch in late 2025 or early 2026 through multiple established distributors with domestic and international reach. Clyra is advancing into the Europe-Middle East-Africa region through partnerships with international distributors."
Richard Ryan, Oak Ridge Financial
(9/30/25)
"BioLargo Inc. has a unique diversified portfolio of solutions that can address the needs of very large global end markets, thus allowing the company to have 'many shots on goal,' which is a testament to its science/technologies. The company's reputation is clearly rising."
Richard Ryan, Oak Ridge Financial
(9/3/25)
"Based on our estimates, we believe that the projected success of Pooph, alongside the current valuation of Clyra Medical, provides investors with underlying support and a conservative degree of upside, while the diverse array of technologies within BioLargo's portfolio offers investors an interesting call option,' if you will. We are reaffirming a Buy rating."
Richard Ryan, Oak Ridge Financial
(8/19/25)
"BioLargo Inc.'s long-duration battery storage initiative continues to make progress, yet it is still early in the process. . .third-party validation has been achieved."
Richard Ryan, Oak Ridge Financial
(7/23/25)
"BioLargo Inc. recently announced a partnership with Verralize Inc., an innovator of next-generation water testing technologies. Verralize's 'lab-on-a-sensor' test kit enables rapid, on-site detection of per- and polyfluoroalkyl substances (PFAS), the so-called 'forever chemicals' regulated under the U.S. Safe Drinking Water Act."
Richard Ryan, Oak Ridge Financial
(5/19/25)
"BioLargo Inc. has regulatory approval for its wound irrigation solution to be used across multiple areas, a large market opportunity exists, it has signed partnering agreements and all participants are working toward commercial launch. . .we believe Clyra has a chance to be one of the most impactful and profitable operations for BioLargo."
Richard Ryan, Oak Ridge Financial
(4/3/25)
"We believe that newsworthy events are likely within several of BioLargo Inc.'s segments in the relatively near term, that a rewrite of the story is at hand. Next up for potential commercialization are the company's wound-healing irrigation solution (U.S. Food and Drug Administration-certified Bioclynse) and its novel PFAS treatment technology, which is on the cusp of having its first municipal project underway."
Richard Ryan, Oak Ridge Financial
(11/18/24)
"BioLargo Inc. announced Q3/24 revenues that again showed strong year over year growth. . .revenues were $4.4M, up from $2.7M a year ago. . .the company's balance sheet remains solid."
11/9/2026 – BioLargo Targets Growing Industrial PFAS Market with MasterClass at International Water Conference
9/10/2026 – BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More
9/9/2026 – BioLargo Townhall and Q2 2026 Earnings Results Webcast and Conference Call on Thursday, September 10th, 2026 - 4:00 PM Eastern Time
9/3/2026 – BioLargo's Subsidiary Clyra Medical Adds Third Distribution Channel Accelerating Commercial Rollout of ViaClyr Wound Irrigation Solution
8/17/2026 – BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%
Important Disclosures
BioLargo Inc. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases.
The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content.
Billboard advertising monthly fees range from $3,000 to $5,000.
This landing page contains a summary of the company that was prepared by that company.
Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company.
The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports.
There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page.
Readers should conduct their own research for all information publicly available concerning the company.
This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.
Streetwise Company Fact Sheet
